Research graph
References from Newer antibiotics for drug-resistant Gram-negative infections in immunocompromised hosts: from pivotal trials to high-risk practice. Local targets link to admitted publications; unresolved targets remain external evidence.
Ceftazidime-avibactam for the treatment of febrile neutropenia in HSCT recipients and acute leukemia patients post induction chemotherapy
10.1038/s41598-024-82795-9 · 2024 · External reference
Meropenem-Vaborbactam versus Ceftazidime-Avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections
10.1128/aac.02313-19 · 2020 · External reference
Empirical and targeted antimicrobial therapy in patients with febrile neutropenia and haematological Malignancy or after haematopoietic cell transplantation: recommendations from the 10th European Conference on Infections in Leukaemia
10.1016/s1473-3099(25)00619-x · 2026 · External reference
Epidemiology of resistant bacterial infections in patients with hematological Malignancies or undergoing hematopoietic cell transplantation in Europe: A systematic review by the European Conference on Infections in Leukemia (ECIL)
10.1016/j.jinf.2025.106571 · 2025 · External reference
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
10.1016/s1473-3099(20)30796-9 · 2021 · External reference
Real-life use of Ceftolozane/Tazobactam for the treatment of bloodstream infection due to Pseudomonas aeruginosa in neutropenic hematologic patients: a matched control study (ZENITH Study)
10.1128/spectrum.02292-21 · 2022 · External reference
The 2022 update of IUIS phenotypical classification for human inborn errors of immunity
10.1007/s10875-022-01352-z · 2022 · External reference
Pharmacokinetics, safety and tolerability of single-dose or multiple-dose cefiderocol in hospitalized pediatric patients three months to less than eighteen years old with infections treated with standard-of-care antibiotics in the PEDI-CEFI phase 2 study
10.1097/inf.0000000000004529 · 2025 · External reference
Safety and efficacy of ceftazidime-avibactam in the treatment of children ≥3 months to <18 years with complicated urinary tract infection: Results from a phase 2 randomized, controlled trial
10.1097/inf.0000000000002395 · 2019 · External reference
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
10.1016/s1473-3099(16)30004-4 · 2016 · External reference
Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
10.1016/s1473-3099(24)00499-7 · 2025 · External reference
Evaluation of beta-lactam therapeutic drug monitoring among US health systems with postgraduate year 2 infectious diseases pharmacy residency programs
10.1093/ajhp/zxac117 · 2022 · External reference
Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050
10.1016/s0140-6736(24)01867-1 · 2024 · External reference
Impact of ceftazidime-avibactam on mortality in bloodstream infections: a cohort study in patients with acute leukemia
10.1177/20499361251362955 · 2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in Pseudomonas aeruginosa of clinical origin
10.1128/aac.00127-24 · 2024 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial
10.1007/s00134-022-06921-9 · 2022 · External reference
Use of cefiderocol in adult patients: descriptive analysis from a prospective, multicenter, cohort study
10.1007/s40121-024-01016-y · 2024 · External reference
Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting
10.1007/s00134-023-07154-0 · 2023 · External reference
Ceftolozane-Tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance
10.1093/cid/cix182 · 2017 · External reference
Ceftazidime-avibactam use in hematology patients: single-center experience
10.1007/s10096-025-05107-7 · 2025 · External reference
A multicenter evaluation of Ceftolozane/Tazobactam treatment outcomes in immunocompromised patients with multidrug-resistant Pseudomonas aeruginosa infections
10.1093/ofid/ofab089 · 2021 · External reference
Ceftazidime-Avibactam regimens for the treatment of bacteremic and non-bacteremic episodes of carbapenemase-producing Enterobacterales infections in immunosuppressed patients
10.3390/pathogens14121300 · 2025 · External reference
A network for advancing prevention and treatment of infections among immunocompromised individuals
10.1001/jamanetworkopen.2025.28383 · 2025 · External reference
How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell Malignancies
10.1182/blood.2019004000 · 2020 · External reference
Shorter antibiotic courses in the immunocompromised: the impossible dream
10.1016/j.cmi.2022.08.007 · 2023 · External reference
Real-world performance of susceptibility testing for cefiderocol: insights from a prospective multicentre study on Gram-negative bacteria
10.1093/jacamr/dlae169 · 2024 · External reference
Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents
10.1093/cid/ciy378 · 2018 · External reference
Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial
10.1001/jama.2022.17034 · 2022 · External reference
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial
10.1001/jama.2018.0438 · 2018 · External reference
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)
10.1016/s1473-3099(23)00184-6 · 2023 · External reference
Developmental pharmacology--drug disposition, action, and therapy in infants and children
10.1056/nejmra035092 · 2003 · External reference
Gut colonization preceding mucosal barrier injury bloodstream infection in pediatric hematopoietic stem cell transplantation recipients
10.1016/j.bbmt.2019.07.019 · 2019 · External reference
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
10.1016/s1473-3099(19)30403-7 · 2019 · External reference
Ceftolozane-Tazobactam population pharmacokinetics and dose selection for further clinical evaluation in pediatric patients with complicated urinary tract or complicated intra-abdominal infections
10.1128/aac.02578-18 · 2019 · External reference
Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship
10.1016/s1473-3099(25)00311-1 · 2026 · External reference
Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model
10.1093/jac/dkaa197 · 2020 · External reference
Cefiderocol therapy among immunocompromised adult patients: a descriptive analysis from a prospective, multicentre cohort study
10.1186/s12879-025-11573-3 · 2025 · External reference
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
10.1111/j.1469-0691.2011.03570.x · 2012 · External reference
Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program
10.1093/cid/ciw133 · 2016 · External reference
Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae
10.1056/nejmc1807634 · 2019 · External reference
RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections
10.1093/cid/ciz530 · 2020 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2024 · External reference
Unresolved reference
2025 · External reference
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
10.1016/j.cmi.2021.11.025 · 2022 · External reference
Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa
10.1007/s10096-019-03573-4 · 2019 · External reference
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
10.1016/s1473-3099(18)30554-1 · 2018 · External reference
Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenemase-producing Enterobacterales in onco-haematologic neutropenic patients (the TARZAN study)
10.1093/jac/dkaf120 · 2025 · External reference
Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections
10.1093/jacamr/dlae146 · 2024 · External reference
Potential of inaccurate cefiderocol susceptibility results: a CLSI AST Subcommittee Advisory
10.1128/jcm.01600-22 · 2023 · External reference
Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) trial: a randomized clinical trial
10.1001/jamasurg.2016.4237 · 2017 · External reference
IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections
10.1093/cid/ciy1029 · 2019 · External reference
Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)
10.1093/cid/civ097 · 2015 · External reference
Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections
10.1093/cid/ciae403 · 2024 · External reference
A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study)
10.1093/cid/ciaa803 · 2021 · External reference
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
10.1016/s1473-3099(17)30747-8 · 2018 · External reference
Clinical impact of ceftazidime/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological Malignancies: a multicentre observational real-world study
10.1093/jac/dkae416 · 2025 · External reference
Once-daily plazomicin for complicated urinary tract infections
10.1056/nejmoa1801467 · 2019 · External reference
Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program
10.1093/cid/ciw378 · 2016 · External reference
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
10.1016/s0140-6736(14)62220-0 · 2015 · External reference
Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial
10.1007/s40121-018-0214-1 · 2018 · External reference
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
10.1016/s1473-3099(20)30731-3 · 2021 · External reference
Effectiveness and safety of ceftazidime/avibactam versus polymyxin B in liver transplant recipients with carbapenem-resistant organism infections: a real-world cohort study
10.1080/20523211.2026.2641111 · 2026 · External reference
Clinical outcomes and risk factors for mortality in recipients with carbapenem-resistant gram-negative bacilli infections after kidney transplantation treated with ceftazidime-avibactam: a retrospective study
10.3389/fcimb.2024.1404404 · 2024 · External reference
